RLAY

Analyst Note: Relay Therapeutics, Inc. (RLAY)

Date: June 20, 2026 Price: $15.88

1. Structural Readiness

State: Context-Only (No structural breakout or coil formation detected in the provided data). Conservative Entry: — Current Price: $15.88 Extension: — Breakout Level: — ATR Current: 6.3% (Very High)

Analysis:

2. The Thesis Layer

Primary Secular Thesis: Biotech & GLP-1 → Oncology (Tier Direct). Company Role: Direct Beneficiary.

RLAY is positioned as a direct beneficiary within the precision oncology secular theme. The company's core value proposition relies on the "Dynamo®" platform to target previously intractable protein drivers, specifically within the PI3Kα pathway. The thesis is strengthened by the company's direct alignment with the "Oncology" tier, focusing on unmet needs in breast cancer and genetic diseases. The evidence suggests a high-confidence exposure to the secular trend of precision medicine, where genetic alterations (specifically PIK3CA mutations) are the primary drivers of treatment selection. The company is not merely a passive participant but a direct developer of therapies (zovegalisib) designed to address specific, high-prevalence mutation subsets in the breast cancer and PROS markets.

3. The Business

Business Model & Industry: Relay Therapeutics is a clinical-stage, small-molecule precision medicine company operating in the Healthcare sector, specifically within the Biotechnology industry. The company utilizes its proprietary Dynamo® platform to develop small molecules that target protein structures previously considered "undruggable."

Operational Status (as of June 20, 2026):

• Lead Candidate (zovegalisib): The company is advancing zovegalisib (RLY-2608) in multiple indications.
• Breast Cancer: In February 2026, the FDA granted Breakthrough Therapy designation to zovegalisib in combination with fulvestrant for adults with PIK3CA mutant HR+/HER2- locally advanced or metastatic breast cancer who have progressed on CDK4/6 inhibitors. This designation was announced in filings dated May 5, 2026, and February 26, 2026.
• Clinical Trials: The company initiated the global Phase 3 registrational study (ReDiscover-2 Trial) in the second quarter of 2025 to evaluate the safety and efficacy of the combination therapy. Additionally, the ReInspire Trial (Phase 1/2) for PIK3CA-related overgrowth spectrum (PROS) and vascular anomalies was initiated in Q1 2025.
• Pipeline Expansion: The company is advancing RLY-8161, an NRAS-selective inhibitor, in patients with NRAS-mutant melanoma and other solid tumors.
• Financial Position: As of March 31, 2026, the company reported selling 14,141,569 shares under its 2024 Sales Agreement, generating $140.4 million in gross proceeds. Management expects existing cash, cash equivalents, and investments to fund planned operating expenses and capital expenditures for at least one year from the date of the March 31, 2026 financial statements.

4. Archetype and Conviction

Archetype: Growth Leader / Clinical Catalyst. Valuation Context: The company is in a "clinical-stage" phase, meaning it has no commercial revenue to date. Its valuation is driven entirely by the probability of success of its clinical programs (specifically the Phase 3 ReDiscover-2 trial) and the Breakthrough Therapy designation. The $140.4 million raised in the 2024 Sales Agreement provides a runway, but the "one year" funding horizon noted in the March 31, 2026 filing implies a need for further capital or positive clinical data before that period expires.

Conviction Stack:

• Thesis Strength: High. The alignment with the precision oncology theme is direct, and the Breakthrough Therapy designation is a significant regulatory milestone that validates the mechanism of action.
• Evidence Quality: Strong. Multiple SEC filings (dated Feb 26 and May 5, 2026) confirm the initiation of Phase 3 trials and the FDA designation. The financial data regarding the ATM (At-The-Market) offering is specific and quantifiable.
• Rerating Potential: High, contingent on Phase 3 data readouts. The Breakthrough Therapy designation is a precursor to potential accelerated approval, which could drive significant rerating if the data supports the hypothesis.

5. Invalidations, Strengtheners, and Gaps

Invalidation Factors:

• Clinical Failure: Any negative top-line data from the ReDiscover-2 Phase 3 trial or the ReInspire Phase 1/2 trial would invalidate the core thesis.
• Capital Exhaustion: If the company burns through the cash runway (funded for one year from March 31, 2026) without securing additional financing or positive data, the business model faces existential risk.
• Regulatory Setback: Withdrawal of the Breakthrough Therapy designation or a negative FDA response to the Phase 3 design would be a major invalidation.

Strengthening Factors:

• Positive Phase 3 Data: Successful interim or top-line results from ReDiscover-2 would strongly strengthen the case.
• New Indications: Expansion of the pipeline or new Breakthrough Designations for other candidates (e.g., RLY-8161).
• Strategic Partnership: Announcement of a licensing deal or partnership to share development costs or accelerate commercialization.

Evidence Gaps:

• Financial Runway Details: While the company states it has funding for "at least one year," the exact cash balance as of March 31, 2026, is not provided in the evidence block, making it difficult to assess the precise timing of the next potential dilution event.
• Trial Enrollment Rates: There is no data on patient enrollment speed for the ReDiscover-2 or ReInspire trials, which is critical for estimating the timeline to data readouts.
• Competitive Landscape: The evidence does not detail the competitive landscape or the specific differentiators of zovegalisib against other PI3K inhibitors in the market.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: FDA Breakthrough Therapy designation for zovegalisib in breast cancer; Initiation of global Phase 3 ReDiscover-2 trial; $140.4 million raised via ATM offering; Dynamo platform targeting intractable targets. Sizing hint: Position size must be reduced to account for binary clinical risk and lack of technical structure; treat as a high-conviction binary event rather than a trend trade. Expected path: Management expects to advance Phase 3 data readouts over the next 12-24 months; stock likely to remain volatile until specific clinical milestones are met or missed. Expected horizon: 12 to 24 months (aligned with Phase 3 trial duration and data readout). Failure mode to watch: Negative Phase 3 data readout or announcement of inability to fund operations beyond the current one-year runway.